PM360

SEPTEMBER 21, 2023

They do not have biosimilar or generic competition available in the market. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. Abbott’s Volt should join the party in early 2026.

Marketing 52

Marketing Competition FDA Electronics 52

Clarivate

APRIL 24, 2023

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. VillageMD’s rollup continued with a March 3 announcement that it was acquiring Starling Physicians, a Connecticut-based physician group, expanding its footprint to 680 practice locations in 26 markets.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

PM360

APRIL 7, 2023

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Expect the nine competitors to explore Kotler’s 4Ps of Marketing to gain share in this lucrative and competitive marketplace.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Leads Sales 52

Clarivate

APRIL 18, 2024

Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. CVS expects to accelerate Oak Street’s footprint expansion in coming years, with previously stated plans of having more than 300 centers in total by 2026. Source: News reports and company releases.

Retail 52

Retail Healthcare Healthcare Physicians 52